Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel-unspn adr (STDAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stada arzneimittel-unspn adr (STDAY) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel-unspn adr (STDAY) Details

STADA Arzneimittel AG engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s principal products include Omeprazole, a stomach medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Atorvastatin, an antilipemic; and Phospholipide, a liver medicine. The Branded Products segment offers non-prescription products. This segment primarily provides APO-go, a Parkinson medicine; Aqualor, a cold medicine based on seawater; Grippostad, a cold medicine; Snup, a nasal preparation; and Ladival, a sunscreen product. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,358 Employees
Last Reported Date: 08/5/15
Founded in 1895

stada arzneimittel-unspn adr (STDAY) Top Compensated Officers

Chairman of The Executive Board
Total Annual Compensation: €2.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.1M
Chief Business Development & Central Services...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2014.

stada arzneimittel-unspn adr (STDAY) Key Developments

Stada-Arzneimittel AG Reports Earnings Results for the Second Quarter Ended June 30, 2015

Stada-Arzneimittel AG reported earnings results for the second quarter ended June 30, 2015. The company has reported that earnings after taxes distributable to shareholders for the second quarter ended June 30, 2015 were EUR 32.41 million, or EUR 0.53 per diluted share, compared to EUR 31.77 million, or EUR 0.52 per diluted share, for the same quarter ended June 30, 2014. Sales for the second quarter ended June 30, 2015 were EUR 539.71 million, compared to EUR 495.37 million for the same quarter ended June 30, 2014.

Stada Arzneimittel Reports Sales Results for the First Half of 2015

Stada Arzneimittel reported sales results for the first half of 2015. For the period, the company's sales rise of 2% year on year to EUR 1,025.9 million. The firm benefited from an improved performance in the second quarter with a positive sales performance in Central Europe and Asia-Pacific & MENA.

Gedeon Richter Plc. Signs License and Distribution Agreement with Stada Arzneimittel AG to Commercialize Richter's Biosimilar Pegfilgrastim in Europe

Gedeon Richter Plc. and STADA Arzneimittel AG announced that the two companies have signed a license and distribution agreement to commercialize Richter's biosimilar Pegfilgrastim in Europe. According to the agreement STADA receives non exclusive distribution rights for the area of geographical Europe (excluding Russia), while Richter retains its rights to distribute and market biosimilar Pegfilgrastim worldwide. Under the terms of the agreement in addition to a payment on the event of signing the contract, STADA is obliged to make further payments each depending on the progress of the project. With the start of marketing, STADA will report the resulting sales and make license related further payments to Richter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAY:US $0.00 USD 0.00

STDAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.117.20 CHF -1.00
Dr Reddy's Laboratories Ltd 4,248 INR +60.70
Endo International PLC $64.00 USD -0.27
Merck KGaA €76.68 EUR -0.51
Medicines Co/The $35.01 USD +0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation STDAY Industry Range
Price/Earnings 40.9x
Price/Sales 1.0x
Price/Book 2.2x
Price/Cash Flow 41.7x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL-UNSPN ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at